Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 31 Aug 2022
FDA authorises Moderna, Pfizer-BioNTech bivalent COVID-19 vaccines for use as a booster dose
31 August 2022 - Today, the US FDA amended the emergency use authorisations of the Moderna COVID-19 Vaccine and the Pfizer-BioNTech ...
Posted by Michael Wonder on 31 Aug 2022
Schedule of Pharmaceutical Benefits - 1 September 2022
1 September 2022 - The September 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Aug 2022
US FDA grants fast track designation for Longeveron’s Lomecel-B product for treatment of hypoplastic left heart syndrome in infants
31 August 2022 - New designation may expedite FDA review and potential approval to address this life-threatening heart condition affecting ...
Posted by Michael Wonder on 31 Aug 2022
New Zealand Pharmaceutical Schedule - 1 September 2022 update
1 September 2022 - The September 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Aug 2022
FDA approves first treatment for acid sphingomyelinase deficiency, a rare genetic disease
31 August 2022 - Today, the US FDA approved Xenpozyme (Olipudase alfa) for intravenous infusion in paediatric and adult patients with ...
Posted by Michael Wonder on 31 Aug 2022
Aquestive Therapeutics receives FDA tentative approval for Libervant (diazepam) buccal film
31 August 2022 - Libervant US market access currently subject to the expiration of Valtoco orphan drug market exclusivity. ...
Posted by Michael Wonder on 31 Aug 2022
ICER publishes evidence report on treatments for obesity management
31 August 2022 - Greater weight loss was seen with semaglutide and with phentermine/topiramate; less weight loss was seen with liraglutide ...
Posted by Michael Wonder on 31 Aug 2022
Scilex announces that the FDA has granted fast track designation for SP-103 (lignocaine 5.4% topical system), next generation triple strength formulation of ZTlido for the treatment of acute low back pain
30 August 2022 - According to the CDC in 2020, low back pain was the most common type of pain reported ...
Posted by Michael Wonder on 31 Aug 2022
CADTH ruling on Spinraza (nusinersen) extinguishes hope for adults needing treatment for spinal muscular atrophy
30 August 2022 - CADTH recommends against reimbursement and access to potentially life-altering treatment for adult spinal muscular atrophy patients, discounting ...
Posted by Michael Wonder on 31 Aug 2022
Pharmaceutical Benefits Scheme supplied medications
30 August 2022 - Key findings about health and population characteristics from the National Health Survey (NHS) and the Pharmaceutical Benefits ...
Posted by Michael Wonder on 31 Aug 2022
Brolucizumab for treating diabetic macular oedema
31 August 2022 - NICE has published evidence-based recommendations on the use of brolucizumab (Beovu) for the treatment of adults ...
Posted by Michael Wonder on 30 Aug 2022
Spinal muscular atrophy community rejoices as 'life-changing' drug Spinraza approved for adults
30 August 2022 - "I have hope again," says Juanita Vernon as the 52 year old tearfully discusses her feelings about ...
Posted by Michael Wonder on 30 Aug 2022
Can the Inflation Reduction Act bring down drug prices?
30 August 2022 - The legislation signed by President Joe Biden on August 16 empowers Medicare to negotiate the prices of ...
Posted by Michael Wonder on 30 Aug 2022
First new kidney treatment in 20 years delays dialysis and transplant
31 August 2022 - Kidney disease is Australia’s silent killer, with nine in 10 patients unaware they have it until too ...
Posted by Michael Wonder on 30 Aug 2022
Outlook Therapeutics re-submits biologics license application for ONS-5010 as a treatment for wet AMD to the US FDA
30 August 2022 - Outlook Therapeutics today announced it has re-submitted its biologics license application to the U.S. FDA for ...